海欣股份：维生素B6注射液通过仿制药一致性评价

Core Viewpoint - The company announced that its subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the "Vitamin B6 Injection," which has passed the consistency evaluation for generic drug quality and efficacy [1] Group 1: Product Approval and Market Impact - The Vitamin B6 Injection is primarily used for the prevention and treatment of Vitamin B6 deficiency, as well as for conditions such as poisoning from isoniazid, pregnancy-related issues, radiation sickness, and vomiting caused by anticancer drugs [1] - The product is classified as a Category A drug under the national medical insurance and is included in the national essential drug list, with projected sales in public medical institutions in China expected to reach approximately RMB 304 million in 2024 [1] - Passing the consistency evaluation is expected to enhance the product's market competitiveness and provide valuable experience for future new drug development, although it will not have a significant impact on the company's current operating performance [1] Group 2: Market Considerations - The company highlighted that drug sales are influenced by national policies, bidding procurement, and market conditions, which introduces uncertainties [1]